Construction of a gyrA plasmid for genetic characterization of fluoroquinolone-resistant Staphylococcus aureus.
We have constructed a gyrA trans-complementation plasmid, pAT512, by cloning the wild-type gyrA gene of Staphylococcus aureus into the expression vector pAT392. Introduction by electrotransformation of pAT512 into a high-level fluoroquinolone resistant mutant of S. aureus (ciprofloxacin MIC = 16 micrograms ml-1) having a gyrA mutation which results in a Ser-84 to Leu substitution, reduced the MICs of norfloxacin and ciprofloxacin for the host of four- and eight-fold, respectively.
Tankovic
J
J
Service de Bactériologie-Virologie-Hygiène, Hôpital Henri Mondor, Université Paris XII, France.
Duval
J
J
Courvalin
P
P
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001483:Base Sequence; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D027081:DNA Gyrase; D015342:DNA Probes; D004250:DNA Topoisomerases, Type II / Q000235:genetics*; D004352:Drug Resistance, Microbial / Q000235:genetics; D024841:Fluoroquinolones; D008969:Molecular Sequence Data; D009154:Mutation; D010957:Plasmids; D013211:Staphylococcus aureus / Q000187:drug effects / Q000235:genetics*
D000890:Anti-Infective Agents; D015342:DNA Probes; D024841:Fluoroquinolones; D002939:Ciprofloxacin; D027081:DNA Gyrase; D004250:DNA Topoisomerases, Type II; C047224:sarafloxacin